A recent draft report from the Institute for Clinical and Economic Review (ICER) has evaluated the cost-effectiveness of therapies for transthyretin amyloid cardiomyopathy (ATTR-CM), warning that in some cases, the price is too high.
The Boston, USA-based pricing watchdog has provided an analysis focusing on Pfizer’s (NYSE: PFE) Vyndamax/Vyndaqel (tafamidis), BridgeBio Pharma’s (Nasdaq: BBIO) acoramidis and Alnylam Pharmaceuticals’ (Nasdaq: ALNY) Amvuttra (vutrisiran).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze